Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
CAMBRIDGE, Mass., Aug. 24, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will participate in two upcoming investor conferences:
- Citi's 11th Annual Biotech Conference
Panel: Gene Therapy: A New Era
Wednesday, September 7, 2016 at 1:00 p.m. Eastern Time
The Mandarin Oriental Hotel, Boston, MA
- 2016 Wells Fargo Healthcare Conference
Fireside Chat: Thursday, September 8, 2016 at 3:30 p.m. Eastern Time
The Westin Boston Waterfront Hotel, Boston, MA
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.dimensiontx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit http://www.dimensiontx.com.
CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]
